Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telo GenomicsTDSGF -16.88% Debt-to-Equity is -1.36 as of Mar. 2026. The stock has 2 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, Telo Genomics ranks worse than 549450% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Telo Genomics's Debt-to-Equity or its related term are showing as below:
TDSGF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.36 Med: 0.01 Max: 0.06
Current: -1.36
During the past 13 years, the highest Debt-to-Equity Ratio of Telo Genomics was 0.06. The lowest was -1.36. And the median was 0.01.
TDSGF's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.33
vs TDSGF: -1.36
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Telo Genomics Debt-to-Equity Related Terms
Telo Genomics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Telo Genomics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDSGF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Telo Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telo Genomics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Telo Genomics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telo Genomics (TDSGF) has a Debt-to-Equity of -1.36 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Telo Genomics and its competitors. According to the industry distribution chart, Telo Genomics ranks #999999 out of 182 companies in the Medical Diagnostics & Research industry.
Is Telo Genomics' Debt-to-Equity too high?
Telo Genomics' current Debt-to-Equity is -1.36. Based on the distribution chart, Telo Genomics ranks #999999 out of 182 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Telo Genomics' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #999999 out of 182 companies for Debt-to-Equity. This places Telo Genomics in the lower half of its industry. The industry median Debt-to-Equity is 0.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Telo Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telo Genomics's current Debt-to-Equity is -1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Debt-to-Equity of -1.36. The current Debt-to-Equity is -1.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Debt-to-Equity is -1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TDSGF has been successfully added to your 
